Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Muscarinic Receptor Antagonist Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Muscarinic receptors are the sites for the neurotransmitters of the parasympathetic autonomic nervous system, acetylcholine, thus muscarinic receptors are responsible for responses including, cardiac slowing, contraction of smooth muscles, vasodilation and increased secretion from exocrine glands. Muscarinic receptor antagonists act on these 5 subtypes of muscarinic receptors i.e., M1, M2, M3, M4, and M5, and induce actions like bronchodilation, reduced gastric acid, reduce secretions from glands, inhibition of bladder contraction, and others. Muscarinic receptor antagonists are indicated for conditions such as chronic obstructive pulmonary disease, overactive bladder, motion sickness, asthma, and myopia. Boehringer Ingelheim, Novartis, AstraZeneca, LENZ Therapeutics, Orient Europharma, and GSK are some of the major market players in muscarinic receptor antagonists. Moreover, there are drugs in the pipeline of pharmaceutical companies for other health conditions.
Key Market Developments:
Approved Drug Molecules and Brand Names for Muscarinic Receptor Antagonists:
Drugs under the Pipeline for Muscarinic Receptor Antagonists:
Clinical Activity and Developments of Muscarinic Receptor Antagonists:
As of June 2023, more than 30 companies have approximately 29 molecules for above 549 diseases. For these molecules, more than 493 clinical trials are being conducted by players across the globe. For instance,
Molecule Name |
Number of Studies |
Glycopyrrolate (PT001) |
19 |
Batefenterol (GSK961081) |
13 |
Darotropium bromide (GSK233705) |
11 |
Xanomeline/Trospium (KarXT) |
11 |
Aroxybutynin/Atomoxetine (AD109) |
6 |
AZD2115 |
6 |
Easyhaler Tiotropium (Tiotropium bromide) |
5 |
Navafenterol (AZD8871) |
5 |
ASM-024 |
4 |
Diphenhydramine/Lorazepam/Zolpidem (SM-1) |
4 |
Oxybutynin/Atomoxetine (AD036) |
4 |
Fluticasone/Batefenterol (FF/GSK-961081) |
3 |
Aceclidine/Tropicamide (PRX-100) |
2 |
Tiotropium bromide inhalation (VR410) |
2 |
Trospium chloride inhalation (ALKS 27) |
2 |
AZD8999 |
1 |
CHF6366 |
1 |
Enablex (Darifenacin) |
1 |
Afacifenacin fumarate (SMP-986) |
1 |
Atropine (CBT-009) |
1 |
Atropine (OT-101 ophthalmic solution) |
1 |
Atropine Sulfate (DE-127) |
1 |
Clonidine/Oxybutynin (OP-014) |
1 |
Glycopyrronium bromide (PSX-1002) |
1 |
Ketamine/Scopolamine |
1 |
Muscarinic receptor antagonists such as Darifenacin, and Tolterodine are used for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. Glycopyrronium is indicated to reduce the volume and acidity of gastric secretions, and airway secretion, and block cardiac inhibitory reflexes during the induction of anesthesia and intubation. Aclidinium is indicated for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. Additionally, there are drug molecules in the clinical trial phases for conditions like myopia, presbyopia, and others.
Download Free Sample Report
Tolterodine, Fesoterodine, Stiolto Respimat (Olodaterol/Tiotropium Fdc), Anoro Ellipta (Umeclidinium/Vilanterol), Tiotropium Bromide Dry Powder Inhaler, and Ultibro (Glycopyrronium/Indacaterol) are some of the approved muscarinic receptor antagonists.
Boehringer Ingelheim, Novartis, AstraZeneca, LENZ Therapeutics, Orient Europharma, and GSK are some of the major market players in muscarinic receptor antagonists.
Major indications for muscarinic receptor antagonists are chronic obstructive pulmonary disease, overactive bladder, motion sickness, asthma, and myopia.
There are a total of 28 molecules in the clinical development phases for muscarinic receptor antagonists.
Key Market Players